Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Summary

Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed. Immunotherapy represents the largest advance in cancer therapy in recent years and has demonstrated promising activity in SCLC. In this study we will investigate whether atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.

Conditions

• Small-cell Lung Cancer

Interventions

DRUG

Atezolizumab

atezolizumab 1200 mg intravenous every 3 weeks in 12 months

Sponsors & Collaborators

• University Hospital of North Norway

  collaborator OTHER

• Alesund Hospital

  collaborator OTHER

• Vestre Viken Hospital Trust

  collaborator OTHER

• University Hospital, Akershus

  collaborator OTHER

• Helse Nord-Trøndelag HF

  collaborator OTHER

• Helse Stavanger HF

  collaborator OTHER_GOV

• Haukeland University Hospital

  collaborator OTHER

• Sorlandet Hospital HF

  collaborator OTHER_GOV

• Ullevaal University Hospital

  collaborator OTHER

• Molde Hospital

  collaborator OTHER

• Helse Fonna

  collaborator OTHER

• Nordlandssykehuset HF

  collaborator OTHER

• Volda Hospital

  collaborator OTHER

• Kristiansund Hospital

  collaborator OTHER

• Sahlgrenska University Hospital

  collaborator OTHER

• Skane University Hospital

  collaborator OTHER

• Karolinska University Hospital

  collaborator OTHER

• Ôrebro University Hospital

  collaborator UNKNOWN

• Gävle Hospital

  collaborator OTHER

• University Hospital, Linkoeping

  collaborator OTHER

• Odense University Hospital

  collaborator OTHER

• Aalborg University Hospital

  collaborator OTHER

• Rigshospitalet, Denmark

  collaborator OTHER

• National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos

  collaborator OTHER

• Kantonsspital Winterthur KSW

  collaborator OTHER

• University Hospital, Basel, Switzerland

  collaborator OTHER

• Insel Gruppe AG, University Hospital Bern

  collaborator OTHER

• Kantonsspital Graubünden

  collaborator OTHER

• Freiburger Spital

  collaborator OTHER

• Klinik Hirslanden, Zurich

  collaborator OTHER

• Kantonsspital Olten

  collaborator OTHER

• Spital STS AG

  collaborator INDUSTRY

• Ente Ospedaliero Cantonale, Bellinzona

  collaborator OTHER

• Cantonal Hospital of St. Gallen

  collaborator OTHER

• St. Olavs Hospital

  collaborator OTHER

• Oslo University Hospital

  collaborator OTHER

• Rijnstate Hospital

  collaborator OTHER

• Isala

  collaborator OTHER

• Zuyderland Medisch Centrum

  collaborator OTHER

• The Netherlands Cancer Institute

  collaborator OTHER

• St. Antonius Hospital

  collaborator OTHER

• Amphia Hospital

  collaborator OTHER

• Medisch Spectrum Twente

  collaborator OTHER

• Erasmus Medical Center

  collaborator OTHER

• Norwegian University of Science and Technology

  lead OTHER

Principal Investigators

• Torstein B Rø, MD, PhD · Norwegian University of Science and Technology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-07-31

Primary Completion

2024-04-01

Completion

2027-04-01

Countries

• Denmark
• Lithuania
• Netherlands
• Norway
• Sweden
• Switzerland

Study Locations